HEINEKEN Holding NV
12.5.2025 12:01:00 CEST | Globenewswire | Press release
Heineken Holding N.V. reports transactions under its current share buyback programme
Heineken Holding N.V. reports transactions under its current share buyback programme
Heineken Holding N.V. reports transactions under its current share buyback programme
Amsterdam, 12 May 2025 - Heineken Holding N.V. (EURONEXT:HEIO; OTCQX: HKHHY), hereby reports transaction details related to the first tranche of up to circa €375 million tranche of its share buyback programme of up to circa €750 million as communicated on 12 February 2025.
From 5 May 2025 up to and including 9 May 2025 a total of 75,015 shares were repurchased on exchange at an average price of € 69.94.
Up to and including 9 May 2025, a total of 771,316 shares were repurchased under the share buyback programme for a total consideration of € 52,342,652.
Heineken Holding N.V. publishes on a weekly basis, every Monday, an overview of the progress of the share buyback programme on its website: https://www.heinekenholding.com/investors/share-information/share-buyback-programme
| Enquiries |
| Media Heineken Holding N.V. | |
| Kees Jongsma | |
| tel. +31 6 54 79 82 53 | |
| E-mail: cjongsma@spj.nl | |
| | |
| Media | Investors |
| Christiaan Prins | Tristan van Strien |
| Director of Global Communications | Global Director of Investor Relations |
| Marlie Paauw | Lennart Scholtus / Chris Steyn |
| Corporate Communications Lead | Investor Relations Manager / Senior Analyst |
| E-mail: pressoffice@heineken.com | E-mail: investors@heineken.com |
| Tel: +31-20-5239355 | Tel: +31-20-5239590 |
Regulatory information:
This press release is issued in connection with the disclosure and reporting obligations as set out in Article 5(1)(b) Regulation (EU) 596/2014 and Article 2(2) of the Commission Delegated Regulation (EU) 2016/1052 that contains technical standards for buyback programs.
Editorial information:
Heineken Holding N.V. engages in no activities other than its participating interest in Heineken N.V. and the management or supervision of and provision of services to that company. HEINEKEN is the world's most international brewer. It is the leading developer and marketer of premium and non-alcoholic beer and cider brands. Led by the Heineken® brand, the Group has a portfolio of more than 340 international, regional, local and specialty beers and ciders. With HEINEKEN’s over 85,000 employees, HEINEKEN brews the joy of true togetherness to inspire a better world. HEINEKEN’s dream is to shape the future of beer and beyond to win the hearts of consumers. HEINEKEN is committed to innovation, long-term brand investment, disciplined sales execution and focused cost management. Through "Brew a Better World", sustainability is embedded in the business. HEINEKEN has a well-balanced geographic footprint with leadership positions in both developed and developing markets. HEINEKEN operates breweries, malteries, cider plants and other production facilities in more than 70 countries. Most recent information is available on www.heinekenholding.com and www.theheinekencompany.com and follow HEINEKEN on LinkedIn and Instagram.
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Genmab A/S13.6.2026 18:45:00 CEST | Press release
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
King Faisal Specialist Hospital & Research Centre13.6.2026 15:57:00 CEST | Press release
KFSH Showcases Trusted AI as the Foundation for Scalable Healthcare Transformation at HLTH Europe 2026
Chery Group13.6.2026 11:39:45 CEST | Press release
FREELANDER 8 Makes First Public Appearance Ahead of Official Abu Dhabi Launch
Hotel Belles Rives13.6.2026 00:11:17 CEST | Press release
Julian Barnes Named Laureate of the 2026 Fitzgerald Prize
Sanofi Winthrop Industrie13.6.2026 00:09:43 CEST | Press release
Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom